Samsung: "All Subsidiaries Showing Balanced Performance Improvement"

On July 9, Samsung Securities raised its target price for Cosmax from 200,000 won to 230,000 won while maintaining its 'Buy' investment recommendation.


Donghee Jung, a researcher at Samsung Securities, stated that Cosmax is currently seeing balanced improvement across all subsidiaries, and price negotiations to ease the burden of rising costs are proceeding smoothly.


[Click e-Stock] "Solid Performance in Korea and Overseas... Cosmax Target Price Raised" View original image

Jung explained, "Major domestic brands are expanding into overseas markets, and following the establishment of the California office at the end of 2024, sales performance with new U.S. customers is materializing faster than expected. The color cosmetics segment, which underperformed in the first half, is likely to narrow its negative growth in the second half, driven by new product launches from each client. In addition, the gel mask segment, currently at a 70% yield rate, is expected to improve toward the end of the year."


He also analyzed that concerns over rising raw material prices are limited. He said, "The increase in raw material prices was absorbed in the first half thanks to 2-3 months' worth of safety inventory, and from June, both new and existing product prices will begin to reflect the cost increases. Since an amicable agreement has been reached with clients, the impact on profitability should be limited." He added, "Cheminova, which was acquired earlier this year, will have little financial impact, as equity method accounting has been confirmed for its 51% stake."


Jung expects the company's second-quarter results to meet market expectations, forecasting sales of 746.5 billion won, up 19.7% year-on-year, and operating profit of 69.4 billion won, up 14.1% year-on-year. Domestic sales are estimated at 484 billion won, as strong growth by major K-beauty brands such as Medicube and Anua in Western Europe helped offset declines in traditional color cosmetics categories. The U.S. subsidiary is projected to achieve 45.1 billion won in sales, exceeding expectations for orders from local indie brand clients and contributing to the group's overall performance.



Jung also noted, "In China, the Shanghai subsidiary is expected to lead with 134.9 billion won in sales, while the Southeast Asia subsidiary is forecast to show higher sales growth and profitability than previously estimated, with the operating margin projected at 9.3%."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing